<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503606</url>
  </required_header>
  <id_info>
    <org_study_id>2011-07-005</org_study_id>
    <nct_id>NCT01503606</nct_id>
  </id_info>
  <brief_title>Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane</brief_title>
  <official_title>Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane, Phase III Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the neonatal outcome and infant neurologic outcome
      whose mother were treated with cefazolin plus clarithromycin for one week or until delivery
      after preterm premature rupture of membrane.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal composite morbidity</measure>
    <time_frame>Participants will be followed for duration of hospital day after delivery, an expected average of 8 weeks</time_frame>
    <description>respiratory distress syndrome(RDS)
bronchopulmonary dysplasia(BPD)
intraventricular hemorrhage(IVH,≥grade 3)
retinopathy of prematurity(ROP,≥grade 3)
necrotizing enterocolitis(NEC,≥stage 2)
proven neonatal sepsis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>infantile neurologic outcome</measure>
    <time_frame>at 6 months and 1 year of corrected age</time_frame>
    <description>The outcome will be evaluated in five sub-domains (development, neurologic examination, Bayley Scales of Infant Development-II, vision, and hearing). The final outcome scale was divided into normal, mild, moderate, and severe disability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Preterm Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>one-week treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>until-delivery treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Cefazolin 1.0gm IVs q 12 hours after randomization for one week</description>
    <arm_group_label>one-week treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>clarithromycin 500mg po bid after randomization for one week</description>
    <arm_group_label>one-week treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Cefazolin 1.0gm IVs q 12 hours after randomization until delivery</description>
    <arm_group_label>until-delivery treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>clarithromycin 500mg po bid after randomization until delivery</description>
    <arm_group_label>until-delivery treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  preterm premature rupture of membrane(PPROM), PA 22+0~34+0wks

          -  ROM &lt;72 hrs before randomization

          -  cervical dilatation &lt;3cm

          -  uterine contraction less than 4 times per 1 hr

        Exclusion Criteria:

          -  Major fetal malformation

          -  Rupture of the membrane &gt;72hrs before randomization

          -  Vaginal bleeding

          -  IIOC (incompetent internal os of cervix)

          -  Placenta previa

          -  Gestational diabetes or overt diabetes

          -  Hypertensive disorders in pregnancy

          -  Liver cirrhosis

          -  Acute renal failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo-young Oh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soo-Young Oh, M.D., PhD</last_name>
    <phone>82-2-3410-3517</phone>
    <email>ohsymd@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-young Oh, MD, PhD</last_name>
      <phone>82-2-3410-3519</phone>
      <email>ohsymd@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Soo-young Oh, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Oh Soo Young</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>preterm premature rupture of membrane</keyword>
  <keyword>antibiotics</keyword>
  <keyword>duration</keyword>
  <keyword>cefazolin</keyword>
  <keyword>clarithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

